Product Description
PH80 is a pherine shown to bind to a subset of peripheral receptors in nasal chemosensory neurons. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01217775)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pherin
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Premenstrual Dysphoric Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01217775 |
PH80-PMD | P3 |
Unknown status |
Premenstrual Dysphoric Disorder |
2017-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/26/2025 |
News Article |
Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting |
|
10/16/2025 |
News Article |
Vistagen to Present at The Menopause Society 2025 Annual Meeting |
|
08/07/2025 |
News Article |
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update |
|
06/17/2025 |
News Article |
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update |